A Phase 2 interventional study of enatumab in Autoimmune Hemolytic Anemia, sponsored by Bing Han. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Bing Han · Phase 2, Interventional, and Treatment
Glucocorticoids are the first-line treatment for wAIHA, but patients are prone to recurrence after dose reduction or discontinuation of glucocorticoids. Birgens et al. 's study found that approximately 55% of patients treated with prednisolone monotherapy experienced recurrence at 36 months. The overall response rate of second-line treatment with rituximab is 70-80%, but the recurrence rate reaches 50%. The response rates of other immunosuppressants, such as cyclosporine, cyclophosphamide, and azathioprine, are relatively low, approximately 30-50%. Patients with chronic hemolysis have recurrent episodes, which affect their survival and quality of life. New treatment methods need to be explored.
Enatumab (BCMA/CD3 bispecific antibody) is a bispecific T-cell articulation antibody targeting BCMA. Its Fab segment can bind to BCMA of plasma cells, plasma blasts and multiple myeloma cells as well as CD3 of T cells. It has shown good efficacy in the treatment of relapsed/refractory multiple myeloma (MM). Enatumab can specifically bind to BCMA on myeloma cells and CD3 on T cells. Through the production and release of cytokines, it activates T cells, promotes T cell proliferation, and releases cytotoxic molecules (including granzyme and perforin), thereby inducing apoptosis of myeloma cells. Plasma cells play a significant role in the pathogenesis of autoimmune diseases and are the main cells that produce autoantibodies. In AIHA, the production of autoantibodies is closely related to the abnormal activation and proliferation of plasma cells. These autoantibodies attack red blood cells, leading to hemolysis. Therefore, theoretically speaking, enatumab may improve the condition of patients with AIHA by inhibiting or eliminating abnormal plasma cells and reducing the production of autoantibodies. At present, there have been two reports internationally on the treatment of refractory AIHA with T-cell agonists targeting BCMA. In 2025, Shi Jun et al. reported two cases where BCAM-targeted T-cell agonists (CM336) successfully treated relapsed AIHA after chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19. Patient 1 (a 10-year-old girl), with a 9-year history of Evans syndrome, still experienced recurrent hemolysis after multiple immunosuppressive treatments. Remission occurred within 14 days after the first CAR-T therapy, but recurred after 6.8 months. There was no response to the second CAR-T. Partial remission was achieved on the 13th day of CM336 treatment, and hemoglobin returned to normal on the 17th day. Case 2 (a 22-year-old female), with a 2-year history of AIHA, had no response to three immunosuppressants and splenectomy. She achieved remission within 10 days after CD19 CAR-T treatment and relapsed after 8.1 months. Partial remission was achieved on the 19th day of CM336 treatment, and hemoglobin returned to normal on the 21st day. The hemolytic indicators such as reticulocytes, LDH and indirect bilirubin in 2 patients decreased significantly and maintained remission for at least 6 months. The B cells and free light chains in the peripheral blood of the two patients decreased rapidly within 2 weeks after medication, and the B cells and plasma cells in the bone marrow were significantly cleared within 12 weeks. In terms of adverse reactions, Patient 1 developed grade 1 skin induration, and both patients presented with hypogammaglobulinemia. However, the overall safety was controllable. CM336 can effectively eliminate residual BCMA⁺ plasma cells, reverse the recurrence of multiple refractory AIHA after CAR-T, and provide a more targeted plasma cell-targeted immune strategy.
97 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 42 are open to participants now.
This study's planned enrollment of 3 is below the median of 24 across 73 interventional studies indexed under Anemia, Hemolytic, Autoimmune.
Browse Anemia, Hemolytic, Autoimmune studies →Bing Han is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
(1) Those with impaired functions of organs such as the heart, liver and lungs; Patients with acute renal insufficiency.
(2) Patients with connective tissue diseases and other secondary AIHA. (3) There is an active infection of hepatitis B virus (HBV), hepatitis C virus (HCV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), human immunodeficiency virus (HIV), or any uncontrolled bacterial, fungal or viral infection.
(4) Complicated with malignant tumors or a history of tumors. (5) When screening, the subjects had other types of uncorrected anemia, such as nutritional anemia, etc.
(6) Had received other BCMA-targeted or CART treatments before screening. (7) Pregnant or lactating women. (8) Activity ≥ grade 2 peripheral sensory/motor neuropathy. (9) Had received treatment with other experimental drugs within 30 days (or as required by local regulations) or within 5 half-lives (whichever is longer) prior to the first use of the intervention drug in this study.
The recommended subcutaneous injection dose of this product is as follows: an incremental dose of 12mg on day 1, an incremental dose of 32mg on day 4, an initial treatment dose of 38mg on day 8, and subsequent treatment doses of 38mg in weeks 4 and 6.
Drug: enatumab
The recommended subcutaneous injection dose of this product is as follows: an incremental dose of 12mg on day 1, an incremental dose of 32mg on day 4, an initial treatment dose of 38mg on day 8, and subsequent treatment doses of 38mg in weeks 4 and 6.
overall response rate (ORR)
The overall response rate (ORR) and complete response rate (CRR) at 3 months. The overall response rate (ORR) is defined as the ratio of patients achieving complete response (CR) plus partial response (PR)
Time frame: 3 months
The incidence and severity of adverse events
Safety analyses include assessments of the incidence and severity of adverse events; all adverse events that occurred or worsened during the treatment period will be reported, as well as adverse events that occurred later but are considered by the investigator to be related to the trial drug.
Time frame: 6-months
Plan to share: Yes — individual participant data would be accepted upon request
Supporting information: Study protocol, Sap, Icf, Csr
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anemia, Hemolytic, Autoimmune→
Bing Han